PubMed=4549213; DOI=10.1002/ijc.2910140402
Jan E. de Vries, Santoso Cornain, Philip Rumke;
Cytotoxity of non-T versus T-lymphocytes from melanoma patients and healthy donors on short- and long-term cultured melanoma cells.
Int. J. Cancer 14:427-434(1974) PubMed=1079770; DOI=10.1016/0014-2964(75)90007-9
Romain Vanwijck, Claire Bouillenne, Shirin Malek-Mansour;
Potentiation and arming of lymphocyte mediated immunity by sera from melanoma patients.
Eur. J. Cancer 11:267-276(1975) PubMed=1101782; DOI=10.1111/j.1749-6632.1975.tb29200.x
Tjwan Hauw The, Harmke A. Huiges, Heimen Schraffordt Koops, Hendrik Bernard Lamberts, Hendrik O. Nieweg;
Surface antigens on cultured malignant melanoma cells as detected by a membrane immunofluorescence method with human sera. Lack of tumor-specific reactions on melanoma lines.
Ann. N. Y. Acad. Sci. 254:528-540(1975) PubMed=1104492; DOI=10.1002/ijc.2910160612
Santoso Cornain, Jan E. de Vries, John G. Collard, Claudia Vennegoor, Ineke van Wingerden, Philip Rumke;
Antibodies and antigen expression in human melanoma detected by the immune adherence test.
Int. J. Cancer 16:981-997(1975) PubMed=6090953; DOI=10.1038/311671a0
Rose Ann Padua, Nigel Charles Barrass, Graham Allan Currie;
A novel transforming gene in a human malignant melanoma cell line.
Nature 311:671-673(1984) PubMed=1697409
Georgia Chenevix-Trench, Nicholas Gordon Martin, Kay Adrian Oswald Ellem;
Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53.
Oncogene 5:1187-1193(1990) PubMed=9354451
Marina Castellano, Pamela M. Pollock, Marilyn K. Walters, Louise E. Sparrow, Louise M. Down, Brian G. Gabrielli, Peter G. Parsons, Nicholas K. Hayward;
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997) PubMed=23039341; DOI=10.1186/1476-4598-11-75; PMCID=PMC3554420
Sara A. Byron, David C. Loch, Candice L. Wellens, Andreas Wortmann, Jia-Yi Wu, John Wang, Kenichi Nomoto, Pamela M. Pollock;
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol. Cancer 11:75.1-75.15(2012) | 
